aTyr Pharma (LIFE) PT Lowered to $16 at RBC Capital
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/2/2026
- Wall St ends higher as stocks reclaim some shine
- Oil settles 1% higher, as US-Iran strikes threaten supplies
- Dell again lifts annual forecasts as AI demand powers record results
- Could Apple’s foldable iPhone be a $14B opportunity? Morgan Stanley weighs in
- Uber stock gains 2% as tech giant cuts 3,300 jobs in major restructuring
- GoPro to merge with Starman Optical in $285M recapitalization deal
- GoPro (GPRO) Halted, News Pending
- Crude Inventory Fell 4.5M Barrels Last Week - EIA
- Wall Street ends lower as higher yields, rising oil prices mark shaky start to September
- TScan cuts 75% of workforce, pivots to solid tumor cell therapy
aTyr Pharma Announces Fourth Quarter and Full Year 2023 Results and Provides Corporate Update
March 14, 2024 4:00 PM EDTPhase 3 EFZO-FIT study of efzofitimod in pulmonary sarcoidosis anticipated to complete enrollment in the second quarter of 2024.
Company launches Individual Patient Expanded Access Program (EAP), allowing access to efzofitimod for patients who complete EFZO-FIT.
Phase 2 EFZO-CONNECT study of efzofitimod in SSc-ILD currently enrolling.
Ended 2023 with $101.7 million in cash, cash equivalents and investments.
Company to host conference call and webcast today, March 14th, at 5:00 p.m. EDT / 2:00 p.m. PDT.
SAN DIEGO, March 14,... More
